To see the other types of publications on this topic, follow the link: Movement and psychiatric disorders.
Journal articles on the topic 'Movement and psychiatric disorders'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Movement and psychiatric disorders.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Perju-Dumbrava, Laura, and Peter Kempster. "Movement disorders in psychiatric patients." BMJ Neurology Open 2, no. 2 (December 2020): e000057. http://dx.doi.org/10.1136/bmjno-2020-000057.
Full textAbstract:
The observability of movement gives it advantages when trying to draw connections between brain and mind. Disturbed motor function pervades schizophrenia, though it is difficult now to subtract the effects of antipsychotic treatment. There is evidence from patients never exposed to these drugs that dyskinesia and even parkinsonism are to some degree innate to schizophrenia. Tardive dyskinesia and drug-induced parkinsonism are the most common movement disorders encountered in psychiatric practice. While D2 dopamine receptor blockade is a causative factor, both conditions defy straightforward neurochemical explanation. Balanced against the need to manage schizophrenic symptoms, neither prevention nor treatment is easy. Of all disorders classified as psychiatric, catatonia sits closest to organic neurology on the neuropsychiatric spectrum. Not only does it occur in the setting of unequivocally organic cerebral disease, but the alterations of consciousness it produces have ‘organic’ qualities even when the cause is psychiatric. No longer considered a subtype of schizophrenia, catatonia is defined by syndromic features based on motor phenomenology. Both severe depression and obsessive-compulsive disorder may be associated with ‘soft’ extrapyramidal signs that resemble parkinsonian bradykinesia. As functional neuroimaging studies suggest, movement and psychiatric disorders involve the same network connections between the basal ganglia and the cerebral cortex.
2
Miguel-Puga, Adán, Gabriel Villafuerte, and Oscar Arias-Carrión. "Psychiatric comorbidities in movement disorders." International Review of Psychiatry 29, no. 5 (July 6, 2017): 516–26. http://dx.doi.org/10.1080/09540261.2017.1322043.
Full text
3
Monahan, R., A. Blonk, H. Middelkoop, M. Kloppenburg, T. Huizinga, N. Van der Wee, and G. M. Steup-Beekman. "POS0708 PSYCHIATRIC DISORDERS IN PATIENTS WITH DIFFERENT PHENOTYPES OF NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS (NPSLE)." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 603.2–604. http://dx.doi.org/10.1136/annrheumdis-2021-eular.423.
Full textAbstract:
Background:Patients with systemic lupus erythematosus (SLE) may present with psychiatric disorders. These are important to recognize, as they influence quality of life and treatment outcomes and strategies.Objectives:We aimed to study the frequency of psychiatric morbidity as classified by the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) in patients with SLE and neuropsychiatric symptoms of different origins.Methods:In the neuropsychiatric SLE (NPSLE) clinic of the Leiden University Medical Center, patients undergo a standardized multidisciplinary assessment by a neurologist, neuropsychologist, vascular internal medicine, rheumatologist, physician assistant and psychiatrist. After two weeks, a multidisciplinary consensus meeting takes place, in which the symptoms are attributed to SLE requiring treatment (major NPSLE) or to minor involvement of SLE or other causes (minor/non-NPSLE). Consecutive patients visiting the NPSLE clinic between 2007-2019 were included. Data of psychiatric evaluation and current medication use were extracted from medical records. The presence of cognitive dysfunction was established during formal neuropsychological assessment.Results:371 consecutive SLE patients were included, of which 110 patients had major NPSLE (30%). Mean age was 44 ± 14 years and 87% was female.The most frequently diagnosed psychiatric disorders in the total group were cognitive dysfunction (42%) and depression (23%), as shown in Table 1. Furthermore, anxiety was present in 5% and psychotic disorders in 4% of patients. In patients with minor/non-NPSLE, especially depression (26% vs 15%) and anxiety (6% vs 2%) were more common than in major NPSLE. Cognitive dysfunction (54% vs 36%) and psychotic disorders (6% vs 4%) were more common in patients with major NPSLE than minor/non-NPSLE.Psychiatric medication was used in 33% of patients, of which antidepressants and benzodiazepines the most frequently (both: 18% in both subgroups). Antipsychotics were more often used in patients with NPSLE (10% vs 7%) and benzodiazepines more often in minor/non-NPSLE (20% vs 14%).In addition, 17 patients (5%) had a history of suicide attempt, which was more common in patients with minor/non-NPSLE than major NPSLE (6% vs 2%).Conclusion:Psychiatric morbidity, especially cognitive dysfunction and depression, are common in patients with lupus and differ between underlying cause of the neuropsychiatric symptoms (minor/non-NPSLE vs major NPSLE).Table 1.Presence of psychiatric diagnoses in patients with SLE and neuropsychiatric symptomsAll patients(n = 371)Minor/non-NPSLE(n = 261)Major NPSLE(n = 110)DSM V diagnosis, n (%)Neurodevelopmental disorder5 (1)2 (1)3 (2)Schizophrenia Spectrum and Other Psychotic Disorders16 (4)10 (4)6 (6)Bipolar and related disorders7 (2)5 (2)2 (2)Depressive disorders84 (23)68 (26)16 (15)Anxiety disorders17 (5)15 (6)2 (2)Obsessive-Compulsive and Related Disorders1 (0)1 (0)0 (0)Trauma- and Stressor-Related Disorders16 (4)12 (5)4 (3)Dissociative Disorders2 (1)2 (1)0 (0)Somatic Symptom and Related Disorders1 (0)1 (0)0 (0)Feeding and Eating Disorders0 (0)1 (0)0 (0)Elimination Disorders0 (0)0 (0)0 (0)Sleep-wake disorders2 (1)2 (1)0 (0)Sexual dysfunctions0 (0)0 (0)0 (0)Gender dysphoria0 (0)0 (0)0 (0)Disruptive, Impulse-Control, and Conduct Disorder0 (0)0 (0)0 (0)Substance-related and addictive disorders9 (2)8 (3)1 (1)Cognitive dysfunction154 (42)95 (36)59 (54)Personality disorders10 (3)9 (3)1 (1)Paraphilic disorders0 (0)0 (0)0 (0)Other mental disorders12 (3)7 (3)5 (5)Medication-Induced Movement Disorders and Other Adverse Effects of Medication0 (0)0 (0)0 (0)Unknown3 (1)3 (1)0 (0)NPSLE = neuropsychiatric systemic lupus erythematosus.Disclosure of Interests:None declared
4
Wetter, T. C. "Insomnia and nocturnal movement disorders." European Psychiatry 26, S2 (March 2011): 2175. http://dx.doi.org/10.1016/s0924-9338(11)73878-0.
Full textAbstract:
Little is known about the prevalence of nocturnal movement disorders in patients with insomnia or psychiatric disorders. However, it is well established that sleep-related motor disorders (movement disorders, parasomnias) are associated with psychopharmacological treatment. In a recent prospective study it has been shown that second-generation antidepressants may induce or worsen symptoms of restless legs syndrome (RLS) which is often associated with insomnia. While pure SSRIs and SNRIs carried an average risk of about 5% for triggering RLS, reboxetine did not seem to induce this syndrome. By contrast, mirtazapine caused or worsened RLS in almost 30% of the patients surveyed (Rottach et al., 2009). Other studies using polysomnography have reported an increased risk of periodic leg movement disorder with antidepressant treatment. It was reported that SSRIs and venlafaxine, but not bupropion, increased the risk of periodic leg movements during sleep (PLMS), suggesting that PLM activity seen in association with antidepressant administration might be serotonergically mediated (Yang et al., 2004). Sleep-related movement disorders may also occur under treatment with first- or second-generation neuroleptics (Cohrs et al., 2008). Administration of antidepressants may also induce the occurence of rapid eye movment (REM) sleep parasomnias such as REM sleep behaviour disorder (RBD) (Thomas et al., 2007). Own preliminary data of an ongoing study revealed that sleep-disordered patients with comorbid psychiatric disorders are more likely to report a variety of nocturnal movement disorders using the Munich Parasomnia Screening Questionnaire. However, whether this result is due to the psychopharmacological medication remains to be determined.
5
Robertson, M. M. "The psychiatric aspects of movement disorders." Current Opinion in Psychiatry 3, no. 1 (February 1990): 83–89. http://dx.doi.org/10.1097/00001504-199002000-00020.
Full text
6
Rigby, Heather, Angela Roberts-South, Hrishikesh Kumar, Leonardo Cortese, and Mandar Jog. "Diagnostic Challenges Revealed from a Neuropsychiatry Movement Disorders Clinic." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 39, no. 6 (November 2012): 782–88. http://dx.doi.org/10.1017/s0317167100015614.
Full textAbstract:
Background:Abnormal movements are frequently associated with psychiatric disorders. Optimized management and diagnosis of these movements depends on correct labeling. However, there is evidence of reduced accuracy in the labeling of these movements, which could result in sub-optimal care.Objective:To determine the consensus inter-rater reliability between a movement disorders neurologist and physicians referring from the community for phenomenology and diagnoses of individuals with co-existing psychiatric conditions and movement disorders.Method:Charts of all consecutive patients seen in a combined Movement Disorders and Neuropsychiatry Clinic between 2001-2009 were reviewed retrospectively. Consensus estimates and kappa values for inter-rater reliability were determined for phenomenology and diagnostic terms for the respective referring source and movement disorders neurologist for each patient.Results:A total of 106 charts were reviewed (62 men and 44 women). Agreement for phenomenology terms ranged from 0% (psychogenic) to 73% (tremor). Only 3 terms had kappa values that met or exceeded criteria for moderate inter-rater reliability. Agreement for diagnosis terms was highest for tardive dyskinesia (83%), drug induced tremor (33%), and drug induced parkinsonism (20%). In 18 of the 22 charts (82%), a diagnosis was made of drug induced movement disorder (DIMD) by the referring physician. In contrast, a diagnosis of DIMD was made in only 54 of 106 charts (51%) after the patients were assessed in the clinic.Conclusions:A movement disorders specialist frequently disagreed with referring physicians' identification of patient phenomenology and diagnosis. This suggests that clinicians would benefit from educational resources to assist in characterizing abnormal movements.
7
Biolsi, Brigitte, Laura Cif, Hassan El Fertit, Santiago Gil Robles, and Philippe Coubes. "Long-term follow-up of Huntington disease treated by bilateral deep brain stimulation of the internal globus pallidus." Journal of Neurosurgery 109, no. 1 (July 2008): 130–32. http://dx.doi.org/10.3171/jns/2008/109/7/0130.
Full textAbstract:
Deep brain stimulation is now accepted as a safe and efficient treatment for movement disorders including selected types of dystonia and dyskinesia. Very little, however, is known about its effect on other movement disorders, particularly for “choreic” movements. Huntington disease is a fatal autosomal-dominant neurodegenerative disorder characterized by movement disorders, progressive cognitive impairment, and psychiatric symptoms. Bilateral chronic stimulation of the internal globus pallidus was performed to control choreic movements in a 60-year-old man with a 10-year history of Huntington disease. Chronic deep brain stimulation resulted in remarkable improvement of choreic movements. Postoperative improvement was sustained after 4 years of follow-up with a marked improvement in daily quality of life.
8
Walsh, Kelda Harris, Katherine Soe, and Shivali Sarawgi. "Psychiatric Treatment and Management of Psychiatric Comorbidities of Movement Disorders." Seminars in Pediatric Neurology 25 (April 2018): 123–35. http://dx.doi.org/10.1016/j.spen.2017.12.002.
Full text
9
Menza, Matthew A., Nancy Grossman, Margaret Van Horn, Ronald Cody, and Nancy Forman. "Smoking and movement disorders in psychiatric patients." Biological Psychiatry 30, no. 2 (July 1991): 109–15. http://dx.doi.org/10.1016/0006-3223(91)90163-g.
Full text
10
Mandolesi, L., G. Piraccini, F. Ambrosini, F. L. Vetere, R. P. Sant’Angelo, R. Raggini, and M. Benassi. "Smooth pursuit eye movements in psychiatric inpatients." European Psychiatry 41, S1 (April 2017): S764—S765. http://dx.doi.org/10.1016/j.eurpsy.2017.01.1438.
Full textAbstract:
IntroductionEye movements are used in several studies as a biomarker in order to evaluate cortical alterations in psychiatric disorders. Pursuit eye movements’ deficits were found both in schizophrenia and in affective disorder patients. Nevertheless, these findings are still controversial.ObjectivesSet up a system to record and evaluate the eye movements in psychiatric patients.AimsTo verify the applicability of a smooth pursuit task in a sample of psychiatric inpatients and to prove its efficiency in discriminating patient and control group performance.MethodsA sample of psychiatric inpatients was tested at psychiatric service of diagnosis and care of AUSL Romagna-Cesena. Eye movement measures were collected at a sampling rate of 60 Hz using the eye tribe tracker, a bar plugged into a PC, placed below the screen and containing both webcam and infrared illumination. Subjects underwent to a smooth pursuit eye movement task. They had to visually follow a white dot target moving horizontally on a black background with a sinusoidal velocity. At the end of the task, a chart of the eye movements done is shown on the screen. Data are off-line analyzed to calculate several eye movement parameters: gain, eye movement delay with respect to the movement of the target, maximum speed and number of saccades exhibited during pursuit.ResultsPatients compared to controls showed higher delay and lower gain values.ConclusionsFindings confirm the adequacy of this method in order to detect eye movement differences between psychiatric patients and controls in a smooth pursuit task.Disclosure of interestThe authors have not supplied their declaration of competing interest.
11
van Harten, P. N., and H. W. Hoek. "Recognition of Movement Disorders in Psychiatry: Video Fragments." European Psychiatry 24, S1 (January 2009): 1. http://dx.doi.org/10.1016/s0924-9338(09)70347-5.
Full textAbstract:
Movement disorders in psychiatry can be divided in those related to an underlying neurological or other somatic disease, related to a psychiatric syndrome, drug induced and psychogenic. In this workshop the typical clinical aspects of each of these movement disorders will be discussed and shown on video with the focus on drug induced. Drug induced can be divided in acute and tardive movement disorders. Acute movement disorders such as acute dystonia, akathisia, parkinsonism and mycoclonus, start short after taking dopamine receptor blocking agents, often an antipsychotic. Once recognized they are relatively easy to treat. Tardive movement disorders such as tardive dyskinesia and tardive dystonia start months or years after using dopamine receptor blocking agents. Treatment is often disappointing, therefore prevention is needed.
12
Berardelli, Isabella, Daniele Belvisi, Massimo Pasquini, Andrea Fabbrini, Federica Petrini, and Giovanni Fabbrini. "Treatment of psychiatric disturbances in hypokinetic movement disorders." Expert Review of Neurotherapeutics 19, no. 10 (July 2, 2019): 965–81. http://dx.doi.org/10.1080/14737175.2019.1636648.
Full text
13
Hardesty, David E., and Harold A. Sackeim. "Deep Brain Stimulation in Movement and Psychiatric Disorders." Biological Psychiatry 61, no. 7 (April 2007): 831–35. http://dx.doi.org/10.1016/j.biopsych.2006.08.028.
Full text
14
Relojo, Dennis. "THE ROLE OF BLOG PSYCHOLOGY IN ONLINE MENTAL HEALTH MOVEMENT: CURRENT STATUS AND IMPLICATIONS." Problems of Psychology in the 21st Century 12, no. 1 (June 20, 2018): 4–7. http://dx.doi.org/10.33225/10.33225/ppc/18.12.04.
Full textAbstract:
Mental disorders contribute significantly to the global burden of disease, as 4 out of the 10 diseases with the highest burden are psychiatric. About 25% of all develop one or more psychiatric and behavioural disorders during their lifetime. Unipolar depression ranges as the leading mental disorder with respect to disability adjusted life years. The major psychiatric disorders like schizophrenia and depression are found in all cultures and result in significant disability. As a result, the cost of mental disorders worldwide needs receiving increasing recognition (Kastrup & Ramos, 2007). Mental health is a global problem – one that needs greater worldwide attention because until now this has not been achieved. For instance, in the US, the world's sliding superpower, the prisons are the functioning mental-health-care system (Kleinman, 2009). Somewhere between a third and a half of all the homeless people in American cities suffer from mental illness.
15
Lorentzos, Michelle S., Isobel Heyman, Benjamin J. Baig, Anna E. Coughtrey, Andrew McWilliams, David R. Dossetor, Mary-Clare Waugh, et al. "Psychiatric comorbidity is common in dystonia and other movement disorders." Archives of Disease in Childhood 106, no. 1 (July 24, 2020): 62–67. http://dx.doi.org/10.1136/archdischild-2020-319541.
Full textAbstract:
ObjectiveTo determine rates of psychiatric comorbidity in a clinical sample of childhood movement disorders (MDs).DesignCohort study.SettingTertiary children’s hospital MD clinics in Sydney, Australia and London, UK.PatientsCases were children with tic MDs (n=158) and non-tic MDs (n=102), including 66 children with dystonia. Comparison was made with emergency department controls (n=100), neurology controls with peripheral neuropathy or epilepsy (n=37), and community controls (n=10 438).InterventionsOn-line development and well-being assessment which was additionally clinically rated by experienced child psychiatrists.Main outcome measuresDiagnostic schedule and manual of mental disorders-5 criteria for psychiatric diagnoses.ResultsPsychiatric comorbidity in the non-tic MD cohort (39.2%) was comparable to the tic cohort (41.8%) (not significant). Psychiatric comorbidity in the non-tic MD cohort was greater than the emergency control group (18%, p<0.0001) and the community cohort (9.5%, p<0.00001), but not the neurology controls (29.7%, p=0.31). Almost half of the patients within the tic cohort with psychiatric comorbidity were receiving medical psychiatric treatment (45.5%) or psychology interventions (43.9%), compared with only 22.5% and 15.0%, respectively, of the non-tic MD cohort with psychiatric comorbidity.ConclusionsPsychiatric comorbidity is common in non-tic MDs such as dystonia. These psychiatric comorbidities appear to be under-recognised and undertreated.
16
Stores, Gregory. "Misdiagnosing sleep disorders as primary psychiatric conditions." Advances in Psychiatric Treatment 9, no. 1 (January 2003): 69–77. http://dx.doi.org/10.1192/apt.9.1.69.
Full textAbstract:
Sleep disorders are relevant to psychiatric practice in a number of ways, including the possibility that they may be misdiagnosed as fundamentally psychiatric conditions in patients of all ages. This risk exists in a wide range of collectively very common sleep disorders which need to be considered in explaining insomnia, excessive sleepiness or disturbed episodes of behaviour associated with sleep (parasomnias). Examples given include circadian sleep–wake cycle disorders (such as the delayed sleep phase syndrome), obstructive sleep apnoea, narcolepsy, Kleine–Levin syndrome, sleep paralysis and rapid eye movement (REM) sleep behaviour disorder. Failure to recognise and treat such disorders is likely to cause and perpetuate psychological problems. Correct recognition requires familiarity with the range and manifestations of sleep disorders.
17
Saint-Cyr, Jean A. "Neuropsychology for Movement Disorders Neurosurgery." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 30, S1 (February 2003): S83—S93. http://dx.doi.org/10.1017/s0317167100003280.
Full textAbstract:
The neuropsychologist plays a crucial role in three phases of the neurosurgical treatment of movement disorder patients, namely screening, outcome evaluation and research. In screening patients, the differential diagnosis of dementia, impact of depression or other psychiatric conditions, and the influence of disease and medication-induced symptoms on cognitive performance must be determined. Postoperatively, systematic evaluations elucidate the cognitive costs or benefits of the procedure. The neuropsychologist is then able to provide feedback and counselling to the professional staff, patient and family to inform management strategies. Neuropsychologists also study alteration of cognitive processing due to lesions or stimulation, which, in tandem with functional imaging, shed light on plasticity in cortical and subcortical processing.
18
Fenton, Wayne S., Crystal R. Blyler, Richard J. Wyatt, and Thomas H. McGlashan. "Prevalence of spontaneous dyskinesia in schizophrenic and non-schizophrenic psychiatric patients." British Journal of Psychiatry 171, no. 3 (September 1997): 265–68. http://dx.doi.org/10.1192/bjp.171.3.265.
Full textAbstract:
BackgroundAlthough movement disorders have been noted among patients never exposed to neuroleptic medications, the specificity of spontaneous dyskinesia to schizophrenia has rarely been examined.MethodBy abstracting detailed case records, we compared the prevalence of dyskinetic movements between 94 neuroleptic-naïve schizophrenic patients and 179 patients with other psychiatric disorders.ResultsDyskinetic movements were more common among patients with schizophrenia than among those with all other diagnoses, and were most often noted in the body areas typically associated with tardive dyskinesia.ConclusionsSpontaneous dyskinesia appears to be relatively specific to schizophrenia and may be intrinsic to the pathophysiology of the disorder.
19
Barrett, Kenneth. "Psychiatric neurosurgery in the 21st century: overview and the growth of deep brain stimulation." BJPsych Bulletin 41, no. 5 (October 2017): 281–86. http://dx.doi.org/10.1192/pb.bp.116.055772.
Full textAbstract:
SummaryAmbulatory deep brain stimulation (DBS) became possible in the late 1980s and was initially used to treat people with movement disorders. Trials of DBS in people with treatment-resistant psychiatric disorder began in the late 1990s, initially focusing on obsessive-compulsive disorder, major depressive disorder and Tourette syndrome. Despite methodological issues, including small participant numbers and lack of consensus over brain targets, DBS is now being trialled in a wide range of psychiatric conditions. There has also been more modest increase in ablative procedures. This paper reviews these developments in the light of contemporary brain science, considers future directions and discusses why the approach has not been adopted more widely within psychiatry.
20
Ilanković, Vera, Andrej N. Ilanković, and Nikola N. Ilanković. "Diagnostic Assessment of Movement Disorders and Psychomotor Deficiency in Residual Schizophrenia." Open Access Macedonian Journal of Medical Sciences 2, no. 2 (June 15, 2014): 239–43. http://dx.doi.org/10.3889/oamjms.2014.038.
Full textAbstract:
Movement disorders and motor deficiency is highly represented among patients in Schizophrenia – residual type (DSM IV): 37% of patients examined in our research had psycho‑motor disturbances. Dominant disturbances are the following: disturbed tonus among 65% of patients, abnormal postural reactions among 90%, abnormal voluntary movements among 75%, disturbed speech among 85%, disturbed static and dynamic postures among 90%. Involuntary movements are present among 20% of patients.Classic neurological diagnostics offers general assessment of the motor status. Standardized clinical motor scales only register the presence and intensity of the motor disturbance. Rehabilitation treatment requires individual and up to date functional diagnostics of the motor deficiency.We would like to stress that psychiatric patients in psychotic, (prepsychotic) and postpsychotic states, besides being mentally ill, also suffer from serious movement disorders (psychomotor disturbances and deficits) which put them into the category of disabled persons, who besides requiring psychiatric (neuropsychiatric) treatment, also require systematic psychomotor and speech rehabilitation.
21
Nudeshima, Jiro, and Takaomi Taira. "A brief note on the history of psychosurgery in Japan." Neurosurgical Focus 43, no. 3 (September 2017): E13. http://dx.doi.org/10.3171/2017.6.focus17255.
Full textAbstract:
In Japan, there has been no neurosurgical treatment for psychiatric disorders since the 1970s. Even deep brain stimulation (DBS) has not been studied or used for psychiatric disorders. Neurosurgery for psychiatric disorders has been thwarted by social taboos for many years, and psychiatrists today seem to simply ignore modern developments and therapies offered by neurosurgery such as DBS. As a result, most patients and their families do not know such “last-resort” options exist.Historically, as in other countries, frontal lobotomies were widely performed in Japan in the 1940s and 1950s, and some Japanese neurosurgeons used stereotactic methods for the treatment of psychiatric disorders until the 1960s. However, in the 1960s and 1970s such surgical treatments began to receive condemnation based on political judgment, rather than on medical and scientific evaluation. Protest campaigns at the time hinged on the prevailing political beliefs, forming a part of the new “left” movement against leading authorities across a wide range of societal institutions including medical schools. Finally, the Japanese Society for Psychiatry and Neurology banned the surgical treatment for psychiatric disorders in 1975. Even today, Japan’s dark history continues to exert an enormous negative influence on neurosurgery for psychiatric disorders.
22
Elefante, Camilla, Giulio Emilio Brancati, Silvia Bacciardi, Sonia Mazzucchi, Eleonora Del Prete, Giovanni Palermo, Daniela Frosini, et al. "Prevalence and Clinical Correlates of Comorbid Anxiety and Panic Disorders in Patients with Parkinson’s Disease." Journal of Clinical Medicine 10, no. 11 (May 25, 2021): 2302. http://dx.doi.org/10.3390/jcm10112302.
Full textAbstract:
Mood and anxiety disorders are the most common neuropsychiatric syndromes associated with Parkinson’s disease (PD). The aim of our study was to estimate the prevalence of lifetime and current anxiety disorders in patients with Parkinson’s Disease (PD), to explore possible distinctive neurological and psychiatric features associated with such comorbidity. One hundred patients were consecutively recruited at the Movement Disorders Section of the Neurological Outpatient Clinic of the University of Pisa. According to the MINI-Plus 5.0.0, 41 subjects were diagnosed with lifetime anxiety disorder (22 with panic disorder) and 26 were diagnosed with current anxiety disorders. Patients with anxiety disorders were more frequently characterized by psychiatric symptoms preceding PD, lifetime major depression and antidepressant treatments. They showed more anxious temperamental traits and scored higher at Parkinson Anxiety Scale (PAS) and persistent anxiety subscale. Current anxiety disorders were associated with more severe psychopathology, depressive symptomatology, and avoidant behavior. Among anxiety subtypes, patients with lifetime panic disorder showed higher rates of psychiatric symptoms before PD, lifetime unipolar depression, current psychiatric treatment, and a more severe psychopathology. Given the overall high impact of anxiety on patients’ quality of life, clinicians should not underestimate the extent of different anxiety dimensions in PD.
23
Meira, Maria Eduarda Antunes de, Giuliano Mannrich, Natahalia Nahas Donatello, and Daiana Cristina Salm. "Antipsychotic-induced movement disorders: integrative review." REVISTA CIÊNCIAS EM SAÚDE 12, no. 3 (September 4, 2022): 44–52. http://dx.doi.org/10.21876/rcshci.v12i3.1259.
Full textAbstract:
Objective: To identify movement disorders induced by antipsychotics. Methods: We selected clinical trials from MEDLINE and LILACS databases without publication date restriction. Studies of antipsychotics as a pharmacological intervention, compared or not to other interventions were included (combined treatments were not included). The primary outcome was movement disorders. Two independent reviewers analyzed the studies and summarized them in an electronic spreadsheet. We assessed the quality of the selected studies using the PEDro scale. Results: Five studies were included in this review. In these studies, it was possible to identify the main psychiatric symptoms and their severity, as well as dyskinetic movements. When a reduction in dyskinetic movements was observed in treatments with both atypical and typical antipsychotics, there were adverse effects. Those included excessive sedation, loss of body mass, vomiting, and leukocytopenia. Conclusion: This study verified the findings in literature on the effects of antipsychotics, including the type of medication, dosage, and form of administration, as well as instruments used to assess the outcome related to movement disorders. It was not possible to determine the best therapeutic dose for managing the disorders due to the significant distinction in dosages and medications. All five studies had some effect related to the drug use or its withdrawal.
24
Dale, Russell C., and Isobel Heyman. "Post-streptococcal autoimmune psychiatric and movement disorders in children." British Journal of Psychiatry 181, no. 3 (September 2002): 188–90. http://dx.doi.org/10.1192/bjp.181.3.188.
Full text
25
Berardelli, Isabella, Massimo Pasquini, Antonella Conte, Matteo Bologna, Alfredo Berardelli, and Giovanni Fabbrini. "Treatment of psychiatric disturbances in common hyperkinetic movement disorders." Expert Review of Neurotherapeutics 19, no. 1 (December 10, 2018): 55–65. http://dx.doi.org/10.1080/14737175.2019.1555475.
Full text
26
Mota, A. "Psychogenic astasia-abasia: A case report and a review of the literature." European Psychiatry 33, S1 (March 2016): S325. http://dx.doi.org/10.1016/j.eurpsy.2016.01.1123.
Full textAbstract:
IntroductionPsychogenic movement disorders are the result of a psychiatric rather than a primary neurological disorder. Astasia-abasia refers to the inability to stand or walk despite having good motor strength and conserved voluntary coordination.ObjectivesStarting from a case report of a patient with an unusual gait disturbance the author intends to discuss the history and knowledge evolution on psychogenic gait disorders until the present time.AimsTo debate the nosology, clinical features, diagnosis and treatment of psychogenic movement disorders.MethodsNon-systematic review of the literature. Case presentation with the exhibition of a video showing the patient's gait.Case presentationA 48-year-old female was admitted to a psychiatry ward after attempting to commit suicide by cutting her throat. On day 3, she suddenly could not walk or stand without help. The neurological examination revealed some inconsistencies and all laboratory, electroencephalogram, and imaging studies performed were normal. After 2 weeks of treatment she started gradually getting better until the full recovery.DiscussionThe gait disturbance presented might be regarded as a form of astasia-abasia. This term was first coined by Paul Blocq (1888) when he described a group of patients who showed inability to maintain an upright posture. Similar movement disorders were previously described as hysteria by authors like Charcot. Nowadays, these case descriptions would be likely considered cases of conversion or psychogenic gait disorder.ConclusionThe etiology of these disorders is still not very well understood. These patients usually benefit from a multidisciplinary approach that includes psychiatry, neurology, physiotherapy, among others. Pharmacological and non-pharmacological treatments should address the underlying psychiatric condition.Disclosure of interestThe author has not supplied his declaration of competing interest.
27
Leiphart, James W., and Frank H. Valone. "Stereotactic lesions for the treatment of psychiatric disorders." Journal of Neurosurgery 113, no. 6 (December 2010): 1204–11. http://dx.doi.org/10.3171/2010.5.jns091277.
Full textAbstract:
Object The use of deep brain stimulation (DBS) has recently been expanded to the investigational treatment of specific psychiatric disorders. Much like movement disorders, the targets selected for DBS are based on past experience with stereotactic lesions. A literature review of past studies incorporating stereotactic lesions for psychiatric disorders was performed to provide historical context and possible guidance for current and future attempts at treating psychiatric disorders with DBS. Methods Original copies of the proceedings of the second, third, fourth, and fifth World Congresses of Psychiatric Surgery meetings were reviewed, and a Medline search was conducted for studies with the word “psychosurgery” and each of 14 highly prevalent psychiatric conditions identified by the National Institute of Mental Health. Postoperative results for 1145 patients with stereotactic brain lesions targeting various anatomical foci were standardized using a 5-point scale (3 [free of symptoms] to −1 [worse]). Each patient was entered into a database as a unique data point and used for this literature review. Results General anxiety disorder and obsessive-compulsive disorder had the greatest reported improvements from anterior capsulotomy, and bipolar disorder, depression, and schizoaffective disorder had the greatest reported improvements from anterior cingulotomy, supporting these areas for DBS investigation. Addiction and schizophrenia showed the least improvement from surgery. Therefore, pursuing the treatment of these disorders with DBS using the targets in these studies may be ineffective. Conclusions This study provides retrospective data that suggest which anatomical focus may be effective to lesion or stimulate for the treatment of each of several psychiatric disorders.
28
Operto, Francesca Felicia, Grazia Maria Giovanna Pastorino, Chiara Padovano, Chiara Scuoppo, Valentina Vivenzio, and Giangennaro Coppola. "Psychogenic Seizures in Adolescents: An “Evergreen” Diagnostic Challenge." BRAIN. Broad Research in Artificial Intelligence and Neuroscience 11, no. 3sup1 (2020): 153–62. http://dx.doi.org/10.18662/brain/11.3sup1/131.
Full textAbstract:
Paroxysmal events are classified as non-epileptic or epileptic symptoms. The first ones are distinguished in psychogenic and organic/physiological paroxysmal events (Lüders et al., 2019). In organic and physiological disorders there are several symptoms: inattention, daydreaming, staring, sleep myoclonus, stereotyped movements, hypnotic spasms, tonic postures, parasomnia, movement disorders. Psychogenic non-epileptic seizures (PNES) are not associated with abnormal brain EEG activity and cannot be explained by other neurological disorders. PNES are also defined as functional neurological disorders and are included among the Conversion Disorders in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (American Psychiatric Association, 2013). This disorder is characterized by symptoms of impaired voluntary or sensorimotor function without the presence of other neurological or clinical conditions.
29
Poznic-Jesic, Milana, Olga Zivanovic, Igor Nikolic, Sasa Radovanovic, Branislav Sakic, and Aleksandar Jesic. "Deep brain stimulation in psychiatry." Medical review 67, no. 1-2 (2014): 28–32. http://dx.doi.org/10.2298/mpns1402028p.
Full textAbstract:
Introduction. Deep brain stimulation is a stereotactic neurosurgical method used in the treatment of Parkinson?s disease and some other movement disorders. The application of deep brain stimulation in the treatment of certain psychiatric disorders has been intensively investigated taking into account the current knowledge of neurobiological basis of mood regulation, cognition, and behaviour. This paper has been aimed at presenting the available data on experience in the application of deep brain stimulation in the treatment of psychiatric disorders. It gives an overview of scientific and professional literature, bearing in mind all the contemporary approaches in the treatment of certain psychiatric disorders. Research results available so far in the treatment of treatment-resistant depression, obsessive-compulsive disorder, Gilles de la Tourette syndrome, addiction and Alzheimer?s dementia, are affirmative concerning the efficacy of the method and low risk of adverse effects. Deep brain stimulation, as a relatively new neurosurgical method in the treatment of psychiatric disorders, is being intensively developed, and it is certainly going to be one of the treatments of choice, primarily of treatment-resistant disorders.
30
Kawanishi, Chiaki, Hideki Onishi, Daiji Kato, Ikuko Kishida, Taku Furuno, Makoto Wada, and Yoshio Hirayasu. "Unexpectedly high prevalence of akathisia in cancer patients." Palliative and Supportive Care 5, no. 4 (October 25, 2007): 351–54. http://dx.doi.org/10.1017/s1478951507000545.
Full textAbstract:
ABSTRACTObjectives:Complications of neuropsychiatric disorders are often detected in cancer patients. Adjustment disorders, depression, or delirium are common psychiatric disorders in these patients, and drug-induced neuropsychiatric problems are sometimes referred for psychiatric consultation. Prochlorperazine and other antiemetic drugs that are phenothiazine derivates are also reported to cause akathisia due to the blockade of the dopamine receptor in the central nervous system, but the prevalence of akathisia in patients undergoing cancer treatment has not been reported. This study seeks to explore the prevalence of such drug-induced syndromes (e.g., akathisia) in this population.Methods:This present study was a prospective study. The subjects of this study were 483 consecutive patients with cancer who had been referred to the Department of Psychiatry in Kanagawa Prefecture Cancer Center from February 1, 2004, to November 30, 2005. Trained psychiatrists conducted a nonstructured psychiatric interview and neurologic examination to establish psychiatric diagnoses according to DSM-IV and the presence or absence of drug-induced extra pyramidal symptoms. The past and current medications used in their cancer treatment were also examined in detail for an accurate evaluation.Results:A psychiatric diagnosis was made in 420 (87.0%) of the 483 cancer patients examined, and akathisia, a drug-induced movement disorder, was unexpectedly prevalent among the patients; 20 of 420 (4.8%) patients had developed akathisia from an antiemetic drug, prochlorperazine.Significance of results:Diagnosing such adverse drug reactions may be difficult due to complicating factors in cancer treatment, and the inner restlessness observed in akathisia is likely to be regarded as a symptom of a primary psychiatric disorder. The authors suggest that oncologists should optimize the use of antiemetic drugs and be aware of akathisia as a possible complication of cancer treatment.
31
van der Salm, Sandra M. A., Anne-Fleur van Rootselaar, Daniëlle C. Cath, Rob J. de Haan, Johannes H. T. M. Koelman, and Marina A. J. Tijssen. "Clinical decision-making in functional and hyperkinetic movement disorders." Neurology 88, no. 2 (December 2, 2016): 118–23. http://dx.doi.org/10.1212/wnl.0000000000003479.
Full textAbstract:
Objective:Functional or psychogenic movement disorders (FMD) present a diagnostic challenge. To diagnose FMD, clinicians must have experience with signs typical of FMD and distinguishing features from other hyperkinetic disorders. The aim of this study was to clarify the decision-making process of expert clinicians while diagnosing FMD, myoclonus, and tics.Methods:Thirty-nine movement disorders experts rated 60 patients using a standardized web-based survey resembling clinical practice. It provided 5 steps of incremental information: (1) visual first impression of the patient, (2) medical history, (3) neurologic examination on video, (4) the Bereitschaftspotential (BP), and (5) psychiatric evaluation. After full evaluation of each case, experts were asked which diagnostic step was decisive. In addition, interim switches in diagnosis after each informational step were calculated.Results:After full evaluation, the experts annotated the first impression of the patients as decisive in 18.5% of cases. Medical history was considered decisive in 33.3% of cases. Neurologic examination was considered decisive in 39.7%, the BP in 8%, and the psychiatric interview in 0.5% of cases. Most diagnostic switches occurred after addition of the medical history (34.5%). Addition of the neurologic examination led to 13.8% of diagnostic switches. The BP results led to diagnostic switches in 7.2% of cases. Psychiatric evaluation resulted in the lowest number of diagnostic switches (2.7% of cases).Conclusions:Experts predominantly rely on clinical assessment to diagnose FMD. Importantly, ancillary tests do not determine the final diagnosis of this expert panel. In general, the experts infrequently changed their differential diagnosis.
32
Wincor, Michael Z. "Sleep Disorders." Journal of Pharmacy Practice 3, no. 4 (August 1990): 221–32. http://dx.doi.org/10.1177/089719009000300404.
Full textAbstract:
Millions of patients are afflicted by a variety of sleep disorders. Sleep can be measured electrophysiologically and described in terms of nonrapid eye movement (NREM) and rapid eye movement (REM) sleep, with REM sleep being dream sleep. Overall, sleep is a cyclic phenomenon, showing a 90-minute periodicity. Sleep disorders are divided into four groups: disorders of initiating and maintaining sleep, disorders of excessive somnolence, disorders of the sleep-wake schedule, and the parasomnias. The parasomnias include sleepwalking, sleep terror, and nightmares. The classic disorders of excessive somnolence include obstructive sleep apnea (an impairment of respiratory function during sleep) and narcolepsy (a genetically transmitted dysregulation of REM sleep). Insomnia may be either transient (eg, associated with jet lag, work shift change, or a disturbing or exciting situation) or chronic (eg, associated with psychiatric disorders or periodic leg movements during sleep). Hypnotics are generally reserved for the treatment of transient or short-term insomnias. Although a number of hypnotics are available, the benzodiazepines are currently accepted as the drugs of choice; selection within the group is based primarily on differences in pharmacokinetic profiles. The practicing pharmacist has the opportunity to play an important role in assessing, recommending treatment, or recommending further evaluation for the many patients who present with insomnia or excessive daytime sleepiness.
33
Göy, D., Ö. Şahmelikoğlu Onur, and N. Karamustafalıoğlu. "Psychiatric manifestations of huntington’s disease: Two case reports." European Psychiatry 64, S1 (April 2021): S409. http://dx.doi.org/10.1192/j.eurpsy.2021.1093.
Full textAbstract:
IntroductionHuntington’s disease (HD) is a progressive neuropsychiatric and degenerative disorder that shows an autosomal dominant inheritance pattern. The principal symptoms of HD are progressive movement disorders, cognitive deterioration, dementia, and certain psychiatric manifestations, which may occur in many different forms, such as depression, psychosis, personality changes.ObjectivesIn this presentation, two female HD patients with psychotic components complicated with suicidal and homicidal thoughts will be reported to better illustrate psychiatric components of HD.MethodsHospitalization records of these two patients with genetically verified HD diagnosis indicated that their psychiatric health precipitously deteriorated in the last decade.ResultsWhile the first patient suffered from severe depression, anxiety, suicidality; persecution ideas, suspiciousness, hostility were noted more prominently in the latter. Moreover, both cases had a positive family history for psychiatric diseases which is one of the hallmarks of HD. Anti-psychotic drug olanzapine, which has minor side-effects on EPS, was found to be highly effective on our HD patients, alleviating the behavioral and psychiatric symptoms of the disease.ConclusionsIn conclusion, HD should be one of the differential diagnoses if patients with psychiatric complaints have accompanying neurological findings such as movement disorders and impaired memory, and great attention should be paid to the extrapyramidal system (EPS) sensitivity of the chosen treatment regime when treating the HD patients,
34
Dale, Russell C., and Fabienne Brilot. "Autoimmune Basal Ganglia Disorders." Journal of Child Neurology 27, no. 11 (July 25, 2012): 1470–81. http://dx.doi.org/10.1177/0883073812451327.
Full textAbstract:
The basal ganglia are deep nuclei in the brain that include the caudate, putamen, globus pallidus, and substantia nigra. Pathological processes involving the basal ganglia often result in disorders of movement and behavior. A number of different autoimmune disorders predominantly involve the basal ganglia and can result in movement and psychiatric disorders. The classic basal ganglia autoimmune disorder is Sydenham chorea, a poststreptococcal neuropsychiatric disorder. Resurgence in the interest in Sydenham chorea is the result of the descriptions of other poststreptococcal neuropsychiatric disorders including tics and obsessive-compulsive disorder, broadly termed pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection. Encephalitic processes affecting the basal ganglia are also described including the syndromes basal ganglia encephalitis, encephalitis lethargica, and bilateral striatal necrosis. Last, systemic autoimmune disorders such as systemic lupus erythematosus and antiphospholipid syndrome can result in chorea or parkinsonism. Using paradigms learned from other autoantibody associated disorders, the authors discuss the autoantibody hypothesis and the role of systemic inflammation in autoimmune basal ganglia disorders. Identification of these entities is important as the clinician has an increasing therapeutic repertoire to modulate or suppress the aberrant immune system.
35
Macchi, Zachary A., Isaiah Kletenik, Caroline Olvera, and Samantha K. Holden. "Psychiatric Comorbidities in Functional Movement Disorders: A Retrospective Cohort Study." Movement Disorders Clinical Practice 8, no. 5 (April 26, 2021): 725–32. http://dx.doi.org/10.1002/mdc3.13226.
Full text
36
Mink, Jonathan, and Roger Kurlan. "Acute Postinfectious Movement and Psychiatric Disorders in Children and Adolescents." Journal of Child Neurology 26, no. 2 (November 22, 2010): 214–17. http://dx.doi.org/10.1177/0883073810378534.
Full text
37
Marques, J., and M. Bajouco. "Can pleiomorphic psychotic symptoms with movement disorders mask wilson’s disease?" European Psychiatry 65, S1 (June 2022): S768. http://dx.doi.org/10.1192/j.eurpsy.2022.1982.
Full textAbstract:
Introduction Wilson’s disease is a rare (1:30,000) autosomal recessive disorder of copper metabolism that is caused by mutations in the adenosine triphosphatase copper transporting beta (ATP7B) gene, located on chromosome 13. The reported percentage of patients with psychiatric symptoms as the presenting clinical feature is 10%-20%. Objectives To present and discuss a rare case admitted in the First Psychotic Episode Inpatient Unit (UIPEP) with pleiomorphic psychotic symptoms and low serum copper and ceruloplasmin and high 24h urine copper. Methods The data was collected through patient and family interviews, as well as from his medical record. We searched Pubmed using MeSH terms: psychotic disorders AND Hepatolenticular Degeneration. Results A twenty-two years old male, without known psychiatric history presented in the Emergency Department with a myriad of psychotic symptoms: motor stereotypes/mannerisms, paranoid delusions and auditory hallucinations. He was admitted in UIPEP, started low-dose antipsychotic medication with good response. As part of the implemented protocol, he did a battery of exams, including Brain CT-scan, EEG, ECG and blood and urine analysis, in which low serum copper and ceruloplasmin stood out, leveraging the suspicion of Wilson´s disease. Therefore, 24h urine copper was done, with 140 mcg/d (reference range < 40 mcg/d). Brain MRI was normal and no Kayser–Fleisher rings were seen by a consulting ophthalmologist. Conclusions Without proper treatment, Wilson’s disease is a progressive and fatal disease. Therefore, it’s of upmost importance to recognize the clinical signs that raise suspicion of this disorder, especially recent onset in young adult of miscellaneous psychotic symptoms with movement disorders. Disclosure No significant relationships.
38
Rogers, Daniel. "Movement disorders." Current Opinion in Psychiatry 6, no. 1 (February 1993): 113–16. http://dx.doi.org/10.1097/00001504-199302000-00022.
Full text
39
Krakow, Barry, Ali Artar, Teddy D. Warner, Dominic Melendrez, Lisa Johnston, Michael Hollifield, Anne Germain, and Mary Koss. "Sleep Disorder, Depression, and Suicidality in Female Sexual Assault Survivors." Crisis 21, no. 4 (July 2000): 163–70. http://dx.doi.org/10.1027//0227-5910.21.4.163.
Full textAbstract:
The role of sleep in psychiatric illness in general, and depression and suicidality in particular, is poorly understood and has not been well researched despite the pervasiveness of sleep complaints in these conditions. As an exploratory, hypothesis-generating study, female sexual assault survivors with posttraumatic stress disorder (n = 153) who had enrolled in a nightmare-treatment program were assessed for subjectively determined sleep breathing and sleep movement disorders. Diagnoses of potential disorders were based on clinical practice parameters and research algorithms from the field of sleep disorders medicine. Potential sleep breathing and sleep movement disorders were present in 80% of the participants (n = 123) and included three subgroups: sleep-disordered breathing only (n = 23); sleep movement disorder only (n = 45); and both sleep disorders (n = 55). Based on the HamiltonDepression Rating Scale and Suicide subscale, participants with potential sleep disorders suffered greater depression (Cohen's d = .73-.96; p < .01) and greater suicidality (Cohen's d = .57-.78; p < .05) in comparison to participants without potential sleep disorders. The group with both sleep disorders suffered from the most severe depression and suicidality. A provisional hypothesis is formulated that describes how sleep disorders may exacerbate depression and suicidality through the effects of chronic sleep fragmentation.
40
Parluhutan Togatorop, Pascanus Lamsihar, and Sri Yenni Trisnawati. "Neuropsychiatric Symptoms in Cerebral Toxoplasmosis with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS): Case Report." International Journal of Research and Review 10, no. 1 (January 23, 2023): 413–18. http://dx.doi.org/10.52403/ijrr.20230146.
Full textAbstract:
Cerebral toxoplasmosis is often caused by the reactivation of pre-existing infections. The increasing number of HIV/AIDS increased cases of cerebral toxoplasmosis. Cerebral toxoplasmosis can show clinical symptoms of neurological and psychiatric. Psychiatric symptoms such as psychosis are often associated with cerebral toxoplasmosis infection. Hemichorea and hemiballism are movement disorders often found in cerebral toxoplasmosis, although movement disorders are less common than other neurological symptoms. We report that a 53-year-old man with complaints of whole-body weakness three days before admitted to the hospital. Patient's appetite decreased. While being treated, he saw an oriental figure walking back and forth as if watching him. Patient also heard voices and complained involuntary movements in the right hand and leg. Neurological examination revealed right hemichorea with characteristics; arrhythmic, irregular, high amplitude, and improved at rest. Psychiatric examination revealed visual and auditory hallucinations. Laboratory examination showed anemia and leukopenia. Chest X-ray revealed a left pleural effusion. Magnetic Resonance Imaging (MRI) of the head with contrast showed multiple lesions with perifocal edema, suspected cerebral toxoplasmosis. Patient received anti-toxoplasmosis and antipsychotic. Patient improved on the sixth day of treatment. Cerebral toxoplasmosis can cause serious complications in patients with HIV/AIDS. Psychotic symptoms such as hallucinations and delusions are often associated with cerebral toxoplasmosis infection. Hemichorea is the most common type of movement disorder in toxoplasmosis cerebral patients related to HIV/AIDS. The main treatment is anti-toxoplasmosis medication. Combination with antipsychotics is effective in treating the symptoms of psychosis and hemichorea, while also inhibiting the replication of Toxoplasma gondii. Keywords: Cerebral Toxoplasmosis, HIV/AIDS, Neuropsychiatric
41
Sennou, Aicha Slassi, Saïd Boujraf, Mohammed Faouzi Belahsen, and Ouafae Messouak. "Psychiatric disorders revealing multiple sclerosis after 20 years of evolvement." Journal of Neurosciences in Rural Practice 05, no. 04 (October 2014): 420–22. http://dx.doi.org/10.4103/0976-3147.140009.
Full textAbstract:
ABSTRACTPrevious research indicates that the onset of psychiatric disorders is sometimes associated with multiple sclerosis (MS) evolving several years later. However, information on why this might occur, and on the outcomes of such patients, is still lacking. We aim to discuss these limitations with the current paper. We describe a 51-year-old female who demonstrated severe anxiety disorder and depression years before developing MS neurological symptoms. The patient was treated for these psychiatric disorders over 20 years. In the last 3 years of her treatment, the patient demonstrated a choreic-type of movement disorder in all her limbs. This disorder is consistent with relapsing-remitting MS. Clinical and magnetic resonance imaging (MRI) examinations demonstrated aspects of MS, without MS being diagnosed conclusively. The visual evoked potential indicated a diagnosis of conduction abnormalities. The established diagnosis was slow relapsing MS. The patient underwent methylprednisolone bolus (1 g/day). This case-study suggests that health professionals should conduct a full neurological assessment when they find atypical psychiatric symptoms in a patient. This would make sure that patients receive a better standard of care, and thus experience a better quality of life.
42
Mulroy, Eoin, Bettina Balint, and Kailash P. Bhatia. "Tardive syndromes." Practical Neurology 20, no. 5 (June 2, 2020): 368–76. http://dx.doi.org/10.1136/practneurol-2020-002566.
Full textAbstract:
Dopamine receptor-blocking antipsychotics, first introduced into clinical practice in 1952, were hailed as a panacea in the treatment of a number of psychiatric disorders. However, within 5 years, this notion was to be shattered by the recognition of both acute and chronic drug-induced movement disorders which can accompany their administration. Tardive syndromes, denoting the delayed onset of movement disorders following administration of dopamine receptor-blocking (and also other) drugs, have diverse manifestations ranging from the classic oro-bucco-lingual dyskinesia, through dystonic craniocervical and trunk posturing, to abnormal breathing patterns. Although tardive syndromes have been an important part of movement disorder clinical practice for over 60 years, their pathophysiologic basis remains poorly understood and the optimal treatment approach remains unclear. This review summarises the current knowledge relating to these syndromes and provides clinicians with pragmatic, clinically focused guidance to their management.
43
Gielkens, Ellen M. J., Sjacko Sobczak, Gina Rossi, Erlene Rosowsky, and S. J. P. van Alphen. "EMDR as a Treatment Approach of PTSD Complicated by Comorbid Psychiatric, Somatic, and Cognitive Disorders: A Case Report of an Older Woman With a Borderline and Avoidant Personality Disorder." Clinical Case Studies 17, no. 5 (August 6, 2018): 328–47. http://dx.doi.org/10.1177/1534650118790413.
Full textAbstract:
Traumatic life events can result in severe psychiatric conditions among which posttraumatic stress disorder (PTSD) is the most prevalent. Due to high comorbidity with other psychiatric diagnoses, PTSD treatment is challenging. In older adults, the presentation of PTSD symptoms is especially complicated because of even higher comorbidity, higher rates with other mental disorders, and cognitive and somatic conditions. Eye movement desensitization and reprocessing (EMDR) is an evidence-based treatment for trauma in younger adults. There is limited empirical research on the treatment effects of EMDR in older adults. Moreover, the impact of successful EMDR treatment on the comorbid disorders, especially personality and cognitive dysfunctions, is unclear. In this case report, EMDR treatment effects for late-onset PTSD with comorbid borderline and avoidant personality disorders, as well as cognitive disorders and multiple somatic problems, will be presented in an older woman.
44
Pan, Weidong, Yu Song, Shin Kwak, Sohei Yoshida, and Yoshiharu Yamamoto. "Quantitative Evaluation of the Use of Actigraphy for Neurological and Psychiatric Disorders." Behavioural Neurology 2014 (2014): 1–6. http://dx.doi.org/10.1155/2014/897282.
Full textAbstract:
Quantitative and objective evaluation of disease severity and/or drug effect is necessary in clinical practice. Wearable accelerometers such as an actigraph enable long-term recording of a patient’s movement during activities and they can be used for quantitative assessment of symptoms due to various diseases. We reviewed some applications of actigraphy with analytical methods that are sufficiently sensitive and reliable to determine the severity of diseases and disorders such as motor and nonmotor disorders like Parkinson’s disease, sleep disorders, depression, behavioral and psychological symptoms of dementia (BPSD) for vascular dementia (VD), seasonal affective disorder (SAD), and stroke, as well as the effects of drugs used to treat them. We believe it is possible to develop analytical methods to assess more neurological or psychopathic disorders using actigraphy records.
45
Boethel, Carl D., Shirley F. Jones, and James A. Barker. "Sleep Movement Disorders and Neurologic Movement Disorders." Sleep Medicine Clinics 7, no. 4 (December 2012): 631–42. http://dx.doi.org/10.1016/j.jsmc.2012.10.004.
Full text
46
Ludlow, Christy L., and Nadine P. Connor. "Dynamic Aspects of Phonatory Control in Spasmodic Dysphonia." Journal of Speech, Language, and Hearing Research 30, no. 2 (June 1987): 197–206. http://dx.doi.org/10.1044/jshr.3002.197.
Full textAbstract:
To understand the voluntary laryngeal movement disorder in spasmodic dysphonia (SD), SD patients were compared with normal controls on speech tasks with different laryngeal motor-control demands. Nine patients with idiopathic chronic SD and no other speech, otolaryngologic, neurologic, or psychiatric disorders were compared with 15 control subjects who were free of such disorders. Speech production tasks required different degrees of dynamic and precise control of vocal fold movement. Phonatory off times were increased in the SD patients, while maximum phonation time, phonatory on time, frequency and intensity control, and reaction times for CV syllables were not affected. On a reaction-time task, the onset of laryngeal movement was not delayed in the SD patients, however, the time between the onset of laryngeal movement and phonatory onset was significantly increased in the SD patients in comparison with the controls. Therefore, SD patients had no difficulty with the onset of laryngeal movement but were slow to achieve phonation, indicating a movement-control disorder affecting vocal fold adduction for phonation onset.
47
Anderson, Karen E., David Stamler, Mat D. Davis, Robert A. Hauser, L. Fredrik Jarskog, Joohi Jimenez-Shahed, Rajeev Kumar, Stanislaw Ochudlo, Joseph McEvoy, and Hubert H. Fernandez. "34 Long-Term Deutetrabenazine Treatment Response in Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonists and Baseline Comorbidities." CNS Spectrums 24, no. 1 (February 2019): 193. http://dx.doi.org/10.1017/s1092852919000282.
Full textAbstract:
AbstractBackgroundTardive dyskinesia (TD) results from exposure to dopamine-receptor antagonists (DRAs), such as typical and atypical antipsychotics. Clinicians commonly manage TD by reducing the dose of or stopping the causative agent; however, this may cause psychiatric relapse and worsen quality of life. In the 12-week ARM-TD and AIM-TD trials, deutetrabenazine demonstrated statistically significant improvements in Abnormal Involuntary Movement Scale (AIMS) scores versus placebo and was generally well tolerated, regardless of baseline DRA use or comorbidities.Study ObjectiveTo evaluate the impact of underlying disease and current DRA use on efficacy and safety of long-term therapy of deutetrabenazine in patients with TD.MethodPatients with TD who completed ARM-TD or AIM-TD were eligible to enter this open-label, single-arm, long-term extension after completing the 1-week washout period and final evaluation in the blinded portion of the trial. Change in AIMS scores from baseline to Week 54 and patients “Much Improved” or “Very Much Improved” (treatment success) on the Clinical Global Impression of Change (CGIC) and Patient Global Impression of Change (PGIC) at Week 54 were analyzed by baseline psychiatric illness type, including mood disorders (bipolar disorder/depression/other) or psychotic disorders (schizophrenia/schizoaffective disorder), and presence or absence of current DRA use.ResultsAt Week 54, meaningful improvements from baseline in mean (standard error) AIMS scores were observed for patients with baseline mood disorders (–5.2[0.93]) and psychotic disorders (–5.0[0.63]), and in patients currently using DRAs (–4.6[0.54]) or not using DRAs (–6.4[1.27]). Most patients with mood disorders (73%) and psychotic disorders (71%) were “Much Improved” or “Very Much Improved” on CGIC at Week 54, similar to patients currently using (71%) or not using (74%) DRAs. The majority of patients with mood disorders (62%) and psychotic disorders (57%), as well as patients currently using (58%) or not using (63%) DRAs, were also “Much Improved” or “Very Much Improved” on PGIC at Week 54. Prior treatment in ARM-TD and AIM-TD did not impact the long-term treatment response. Underlying psychiatric disorder and concomitant DRA use did not impact the occurrence of adverse events (AEs). The frequencies of dose reductions, dose suspensions, and withdrawals due to AEs were low, regardless of baseline psychiatric comorbidities and DRAuse.ConclusionsLong-term deutetrabenazine treatment demonstrated meaningful improvements in abnormal movements in TD patients, which were recognized by clinicians and patients, regardless of underlying psychiatric illness or DRAuse.Presented at: American Psychiatric Association Annual Meeting; May 5–9, 2018, New York, New York, USAFunding Acknowledgements: This study was supported by Teva Pharmaceuticals, Petach Tikva, Israel.
48
Wajeeha Qayyum, Muhammad Shahid Iqbal, Sohail Khan, Muhammad Fozan Khan, Mohammad Jawad, and Fawad Jan. "Spectrum of neurological diseases in patients presenting to a tertiary care hospital of Peshawar." Professional Medical Journal 29, no. 03 (February 28, 2022): 356–61. http://dx.doi.org/10.29309/tpmj/2022.29.03.6302.
Full textAbstract:
Objective: The aim of our study was to note the spectrum of neurological diseases in Out Patient department of hospital. Study Design: Observational Cross Sectional study. Setting: Rehman Medical Institute, Peshawar. Period: Jan 2019 to June 2019. Material & Methods: All the patients presenting/referred to neurology OPD were included. There demographic characteristics, level of disability and diagnosis was noted on proforma. The diagnosis was made by neurologist and the neurological diseases were grouped according to International Classification of Disease in different categories. Data was entered and analyzed on SPSS 22. Results: Out of 455 patients, 54.7% (n=249) were female. Mean age was 42.92±17.69. 54.7% (n=249) belong to urban area. Psychiatric illness was the most common group of illness accounted for 29.5% (n=134) followed by nerve disorders 23.3 %( n=106) and Headaches 23.10 %( n=105), muscular disorders 14.70% (n=67), vascular diseases 13.40% (n=61) and epilepsy 5.9% (n=27).Vascular diseases were significantly more in males (P value < 0.05). Female predominance was observed in nerve and psychiatric disorders (P value < 0.05). Vascular diseases, movement disorders and dementia was observed in elder age group. (P-value < 0.05). Epilepsy effected pediatric, headache and psychiatric illness were seen in young age and nerve disorder were common in middle aged people mostly. (P value <0.05). Conclusion: Psychiatric disorder was the top most diagnosis followed by nerve disorder and headache. Most of the disorders were significantly more in specific age groups and few were gender specific.
49
Yegya-Raman, Nikhil, Rehan Aziz, Daniel Schneider, Anthony Tobia, Megan Leitch, and Onyi Nwobi. "A Case of Sporadic Creutzfeldt-Jakob Disease Presenting as Conversion Disorder." Case Reports in Psychiatry 2017 (2017): 1–4. http://dx.doi.org/10.1155/2017/2735329.
Full textAbstract:
Background. Creutzfeldt-Jakob disease is a rare disorder of the central nervous system. Its initial diagnosis may be obscured by its variable presentation. This case report illustrates the complexity of diagnosing this disease early in the clinical course, especially when the initial symptoms may be psychiatric. It offers a brief review of the literature and reinforces a role for consultation psychiatry services. Methods. PUBMED/MEDLINE was searched using the terms “Creutzfeldt-Jakob disease”, “psychiatric symptoms”, “conversion disorder”, “somatic symptom disorder”, “functional movement disorder”, and “functional neurologic disorder”. Case. The patient was a 64-year-old woman with no prior psychiatric history who was initially diagnosed with conversion disorder and unspecified anxiety disorder but soon thereafter was discovered to have Creutzfeldt-Jakob disease. Discussion. This case highlights the central role of psychiatric symptoms in early presentations of Creutzfeldt-Jakob disease. Still, few other cases in the literature report functional neurological symptoms as an initial sign. The consultation psychiatrist must remain alert to changing clinical symptoms, especially with uncharacteristic disease presentations.
50
Ozdilek, Betul, Kayıhan Uluc, and Dilek I. Gunal. "Bilateral striopallidodentate calcinosis presenting with psychiatric symptoms and speech disorders." Acta Neuropsychiatrica 24, no. 5 (October 2012): 310–13. http://dx.doi.org/10.1111/j.1601-5215.2012.00653.x.
Full textAbstract:
Ozdilek B, Uluc K, Gunal DI. Bilateral striopallidodentate calcinosis presenting with psychiatric symptoms and speech disorders.Background: Bilateral striopallidodentate calcinosis (BSPDC), also known as Fahr's disease, is a rare neurodegenerative disorder characterised by the deposition of calcium and other minerals in the basal ganglia, centrum semiovale and cerebellum. It is usually idiopathic. Its clinical manifestations vary from asymptomatic individuals to neuropsychiatric abnormalities, movement disorders, cerebellar symptoms and cognitive impairments.Methods: Five cases of BSPDC – all of which include psychiatric symptoms and speech problems – from two families are documented in this article.Conclusion: The most important diagnostic marker is the demonstration of symmetrical intracranial calcifications. Computerised tomography of the brain is the most frequently used radiologic method to diagnose BSPDC.